Study guide

20.1 The APRN Consultation Process & Communicating Recommendations

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

20.1 The APRN Consultation Process & Communicating Recommendations

Key Takeaways Explain This Topic AI

Consult, collaborate and coordinate care carries 10% of the CARN-AP blueprint, roughly 14 to 15 items.

In a true consultation the consultee retains authority to accept or reject the recommendation, which distinguishes consultation from referral and from co-management.

The highest-rated consultation activities are supporting collaboration with nursing and other colleagues to implement the plan (index 10.25) and documenting communication, rationales for changes and collaborative discussions in the plan of care (10.14).

Recommendations are more likely to be implemented when they are specific, prioritized, limited in number, and written with the ordering parameters the consultee needs.

Consultation effectiveness improves when the patient and other stakeholders are involved in decision making and role responsibilities are explicitly negotiated.

Last updated: September 2026

20.1 The APRN Consultation Process & Communicating Recommendations

Quick Answer: Activity Area IV — consult, collaborate and coordinate care with health professionals and peer specialists — is 10% of the CARN-AP (14 to 15 items) . In a consultation , the consultee retains authority to accept or reject the recommendation; in a referral , care is transferred; in co-management , responsibility is shared. The two highest-rated activities in this area are supporting collaboration with colleagues to implement the plan (index 10.25) and documenting communication, rationales for changes, and collaborative discussions in the plan of care (10.14).

1. Three Distinct Relationships

Model Who holds decisional authority Typical addiction example

Consultation The requesting clinician Hospitalist asks the addiction APRN how to manage withdrawal in a patient admitted for pneumonia; the hospitalist writes the orders

Referral The receiving clinician, for the referred problem Primary care refers a patient to an opioid treatment program for methadone

Co-management Shared and explicitly divided Obstetrics manages pregnancy while the addiction APRN manages buprenorphine, with defined boundaries

Why this matters clinically: a consultant who writes orders in a consultation relationship without agreement creates confusion, duplicated or conflicting orders, and medicolegal ambiguity. A consultant who is asked to co-manage but behaves as an advisor leaves the patient without an owner. Clarify the model in the first conversation .

2. The Consultation Sequence

Clarify the actual question. The stated reason ("evaluate for substance abuse") is often not the real one ("the nurses are afraid of this patient" or "we need to know if we can safely discharge"). Ask the consultee directly what decision they are trying to make.

Gather independent data. Interview the patient, examine, review the record, check the PDMP, review toxicology. The practice analysis's highest-rated assessment activity is synthesizing complex data from interview, examination and diagnostics.

Speak with the patient about the consultation itself. Explain who asked, what you will and will not share, and what the patient wants from the visit. Patients frequently assume an addiction consultant is an investigator.

Formulate. A diagnosis, a severity statement, the specific risks, and the decision-relevant answer.

Communicate. Direct verbal contact with the consultee for anything urgent or likely to be contested, followed by a written note.

Document the rationale , not just the recommendation. The next clinician needs to know why, or the plan will be abandoned at the first handoff.

Follow up. Check whether the recommendation was implemented and whether it worked, and adjust.

3. Writing Recommendations That Get Implemented

Weak recommendation Strong recommendation

"Consider treatment for alcohol withdrawal." "Start symptom-triggered lorazepam 2 mg PO/IV for CIWA-Ar 10 or higher, reassess q1h until two consecutive scores below 8, then q4h. Thiamine 500 mg IV q8h x 3 days before any dextrose."

"Patient would benefit from MOUD." "Recommend buprenorphine/naloxone induction today: 4 mg SL now given COWS 14, reassess in 90 minutes, additional 4 mg if COWS remains 8 or higher, target 16 mg day 1. I have arranged an OBAT appointment for Thursday at 10 a.m."

"Suggest addiction follow-up." "I have scheduled an appointment at the Grayken clinic on 9/18 at 2 p.m. and given the patient the address and a bus pass. Please include this in the discharge summary."

Four rules:

Prioritize. Lead with the one recommendation that matters most. A list of nine equally weighted suggestions gets none of them implemented.

Limit the number. Three to five actionable items per note.

Be specific enough to order from. Drug, dose, route, frequency, monitoring parameter, and stop criterion.

Own the logistics you can own. Making the appointment yourself converts a recommendation into a completed action.

4. Handling Disagreement

The consultee may reject the recommendation. That is legitimate — they retain authority and they hold information the consultant may not.

Ask what is driving the disagreement. It is often a practical constraint (formulary, nurse staffing, pharmacy policy) rather than a clinical objection.

Offer a second-best option that fits the constraint. A partially implemented plan beats an ignored one.

Document the recommendation, the response, and any residual risk in neutral, non-accusatory language.

Escalate only for genuine patient-safety issues , through the agreed institutional pathway, and tell the consultee you are doing so.

A pattern to recognize: repeated rejection of the same evidence-based recommendation across many consultations is a systems problem , not an interpersonal one, and belongs in quality improvement rather than in another individual argument.

5. Consulting About Stigma

A large share of addiction consultation requests carry an unstated subtext: the team is frustrated, frightened, or morally uncomfortable. The APRN's most valuable consultative contributions are frequently not pharmacologic:

Reframe behavior as a symptom. "Leaving against medical advice at hour 20 is usually untreated withdrawal, not rejection of care. If we treat the withdrawal, the AMA rate drops."

Name the countertransference without accusation. "This patient is hard to like right now. That is normal. Here is how we keep the plan clinical."

Give the team a script. Specific language for the moment the patient demands more medication is more useful than a lecture on stigma.

Model the language. Say "unexpected toxicology result" out loud on rounds and it propagates.